---
id: 136
title: Strongyloides stercoralis and Hyperinfection Syndrome
category: organisms
subcategory: parasites
tags: [Strongyloides, hyperinfection, ivermectin, eosinophilia, autoinfection]
difficulty: medium
---

## Question

How is *Strongyloides* diagnosed and managed? Use the **"Screen Before Immunosuppression, Ivermectin, Hyperinfection = High Mortality"** framework.

## Answer

### ***Strongyloides stercoralis* Overview:**

**Transmission:**
- **Soil contact** (bare feet) → filariform larvae penetrate skin
- **Endemic:** Tropics/subtropics (Southeast Asia, sub-Saharan Africa, Latin America), rural southeastern US

**Unique Feature:**
- **Autoinfection cycle:** Larvae can complete entire lifecycle within human host → **lifelong infection** if untreated
- **Can persist decades** after leaving endemic area

### **Clinical Syndromes:**

**Uncomplicated (Chronic) Infection:**
- **Asymptomatic** (most common) OR
- **GI symptoms:** Abdominal pain, diarrhea, nausea
- **Skin:** **Larva currens** (urticarial serpiginous rash, migrates rapidly, buttocks/thighs)
- **Pulmonary:** Cough, wheezing (larval migration through lungs)
- **Eosinophilia** (common, but can be absent)

**Hyperinfection Syndrome:**
- **Massive larval burden** due to **accelerated autoinfection**
- **Risk factors:** **Corticosteroids** (≥20mg prednisone × >2 weeks), HTLV-1, transplant, hematologic malignancies
- **Presentation:**
  - **Severe GI:** Abdominal pain, diarrhea, GI hemorrhage, ileus, bowel perforation
  - **Pulmonary:** Dyspnea, hemoptysis, ARDS, respiratory failure
  - **Gram-negative bacteremia/sepsis** (larvae carry gut bacteria into bloodstream)
  - **CNS:** Meningitis (Gram-negative), brain abscesses
- **Eosinophilia often ABSENT** (corticosteroids suppress eosinophils)
- **High mortality:** >50% if untreated

**Disseminated Strongyloidiasis:**
- **Larvae in organs** beyond GI/lungs (liver, CNS, kidneys)
- **Even higher mortality** (70-90%)

### **Diagnosis:**

| Test | Sensitivity | Notes |
|------|-------------|-------|
| **Stool O&P (×3)** | **50-70%** (low) | Larvae intermittently shed, multiple samples needed |
| **Serology (ELISA, IgG)** | **>90%** | **Most sensitive**, **test of choice** for screening |
| **Agar plate culture** | 80-90% | Larvae create tracks on agar, more sensitive than stool O&P |
| **Sputum/BAL** | Variable | Larvae in sputum (if hyperinfection) |

**Key Point:** **Serology is most sensitive** for screening (especially before immunosuppression)

### **Treatment:**

**Uncomplicated Infection:**
- **Ivermectin** 200 mcg/kg PO daily × **2 days**
- **Check stool** at 2 weeks, 1 month, 3 months (ensure cure)

**Hyperinfection Syndrome/Disseminated:**
- **Ivermectin** 200 mcg/kg PO/SL (sublingual if ileus) daily × **≥2 weeks** (continue until stool/sputum negative × 2 weeks)
- **Alternative:** Albendazole 400mg PO BID (less effective, use if ivermectin unavailable)
- **Reduce immunosuppression** if possible
- **Broad-spectrum antibiotics** (for Gram-negative bacteremia)
- **High mortality** despite treatment

**Prevention:**
- **Screen all patients** from endemic areas **BEFORE starting immunosuppression**
  - Especially: Corticosteroids, transplant, HTLV-1+, refugees/immigrants
- **Empiric ivermectin** if cannot wait for serology results (e.g., urgent transplant)

## Key Points

### **Why Screen Before Immunosuppression:**
- **Asymptomatic chronic infection** can progress to **fatal hyperinfection** with corticosteroids/immunosuppression
- **Mortality >50%** if hyperinfection develops
- **Ivermectin prophylaxis** (200 mcg/kg × 2 days) prevents hyperinfection

### **High-Risk Populations for Screening:**
- **Refugees/immigrants** from endemic areas (Southeast Asia, Africa, Latin America, rural SE US)
- **Veterans** (especially Southeast Asia)
- **HTLV-1 positive** (co-endemic areas, impaired cellular immunity against *Strongyloides*)
- **Pre-transplant** (solid organ, HSCT)
- **Starting chronic corticosteroids** (≥20mg prednisone × >2 weeks)

### **HTLV-1 Co-Infection:**
- **HTLV-1** (human T-lymphotropic virus-1) endemic in same areas as *Strongyloides*
- **HTLV-1 impairs Th2 response** → cannot control *Strongyloides*
- **Higher risk** of hyperinfection, worse outcomes
- **Screen for both** if from endemic area

### **Gram-Negative Bacteremia in Hyperinfection:**
- **Larvae carry gut bacteria** (E. coli, Klebsiella, Enterobacter) into bloodstream
- **Recurrent Gram-negative bacteremia** = red flag for *Strongyloides*
- **Polymicrobial bacteremia** common
- **Gram-negative meningitis** can occur

### **Eosinophilia:**
- **Present in chronic infection** (50-80% of cases)
- **Often ABSENT in hyperinfection** (corticosteroids suppress eosinophils)
- **Do NOT rely on eosinophil count** to rule out *Strongyloides*

### **Clinical Pearls:**
- **Screen before immunosuppression** (serology most sensitive)
- **Ivermectin 200 mcg/kg × 2 days** (uncomplicated)
- **Hyperinfection:** Ivermectin daily × ≥2 weeks (until stool/sputum negative × 2 weeks)
- **High mortality (>50%)** if hyperinfection develops
- **Larva currens** (urticarial serpiginous rash, buttocks/thighs) = pathognomonic
- **Recurrent Gram-negative bacteremia** = think *Strongyloides*
- **HTLV-1 co-infection** = higher risk

## Sources

- [CDC: Strongyloidiasis Guidelines 2024]
- [IDSA: Strongyloidiasis Management 2023]

## Media

N/A
